Liyi Li

Liyi Li

Auto-generated profile, based on publicly available information

Liyi Li

Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
YYYao-Jun Yu
Yao-Jun Yu
NSNa Shan
Na Shan
LLLi-Yi Li
Li-Yi Li
YZYue-Sheng Zhu
Yue-Sheng Zhu
LLLi-Miao Lin
Li-Miao Lin
ZCZhenzhai Cai
Zhenzhai Cai
Immunotherapy based on immune checkpoint inhibitors (ICIs) has provided revolutionary results in treating various cancers. However, its efficacy in colorectal cancer (CRC), especially in microsatellite stability-CRC, is limited. This study aimed to observe the efficacy of personalized neoantigen vaccine in treating MSS–CRC patients with recurrence or metastasis after surgery and chemotherapy. Candidate neoantigens were analyzed from whole-exome and RNA sequencing of tumor tissues. The safety and immune response were assessed through adverse events and ELISpot. The clinical response was evaluated by progression-free survival (PFS), imaging examination, clinical tumor marker detection, circulating tumor DNA (ctDNA) sequencing. Changes in health-related quality of life were measured by the FACT-C scale. A total of six MSS–CRC patients with recurrence or metastasis after surgery and chemotherapy were administered with personalized neoantigen vaccines. Neoantigen-specific immune response was observed in 66.67% of the vaccinated patients. Four patients remained progression-free up to the completion of clinical trial. They also had a significantly longer progression-free survival time than the other two patients without neoantigen-specific immune response (19 vs. 11 months). Changes in health-related quality of life improved for almost all patients after the vaccine treatment. Our results shown that personalized neoantigen vaccine therapy is likely to be a safe, feasible and effective strategy for MSS–CRC patients with postoperative recurrence or metastasis.

25 June 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LLLiyi Li
Liyi Li
QCQin Chen
Qin Chen
YYYaojun Yu
Yaojun Yu
HCHui Chen
Hui Chen
MLMingdong Lu
Mingdong Lu
YLYi Liao
Yi Liao

1 March 2018 in Acta Chromatographica
Verified
Journal Article
Open access
LLLiyi Li
Liyi Li
LHLiming Hu
Liming Hu
BCBingbao Chen
Bingbao Chen
YDYanwen Dong
Yanwen Dong
ZLZixia Lin
Zixia Lin
SWshuanghu wang
shuanghu wang
In this study, we developed a urine metabolomic method by gas chromatography–mass spectrometry (GC–MS) combination with biomedical results to evaluate the effect of activated carbon on methomyl poisoning rats. The rats were divided into four groups, methomyl group, two activated carbon treatment group, and control group. According to the biochemical results, it indicated that activated carbon treated rats could cause liver and kidney function changes. According to the urine metabolomics results, activated carbon treatment group (10 min) and activated carbon treatment group (30 min) could be distinguished from methomyl group, and activated carbon treatment group (10 min) could be separated from activated carbon treatment group (30 min) rats, which indicated that the treatment of rats by activated carbon in different time had a different effect. The results indicate that metabolomic method by GC–MS may be useful to elucidate activated carbon treated on methomyl poisoning rats.